China AI for Biotech Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China AI for Biotech Market was valued at USD 1.40 billion in 2025 and is projected to reach USD 2.35 billion by 2032, growing at a CAGR of approximately 7.7% during 2026–2032.
China AI for Biotech Market Highlights
| Report Metric | Details |
| Report Name | China AI for Biotech Market |
| Market Size 2025 | USD 1.40 billion |
| Market Size 2032 | USD 2.35 billion |
| Absolute Growth 2025–2032 | USD 0.95 billion |
| CAGR 2026–2032 | 7.7% |
| Peak Annual Growth | 10.1% in 2029 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Application Area, 2025 | Drug Discovery (49% share) |
| Leading Technology Type, 2025 | Machine Learning (45% share) |
| Leading Distribution Channel, 2025 | Biotech Cloud Platforms (43% share) |
| Leading End User, 2025 | Biopharmaceutical Companies (48% share) |
| Fastest-Growing Application Area | CRISPR Analysis (10.2% CAGR) |
| Fastest-Growing Technology Type | AI Algorithms (8.9% CAGR) |
| Fastest-Growing Distribution Channel | Specialized B2B Portals (10.0% CAGR) |
| Fastest-Growing End User | Genetic Engineering Labs (10.4% CAGR) |
| Growing Sector | biopharmaceutical sector |
| Key End Users | biopharmaceutical companies, genetic engineering labs, genomics firms, academic biotech research centers |
China AI for Biotech Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Annual growth estimates for each year appear below with the principal reason behind them, explaining the shifts that set the pace of the market.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 8.3 | The biopharmaceutical sector showed strong demand for AI technologies in drug development. |
| 2023 | 8.7 | Increased funding for AI research boosted applications in biotechnology across various institutions. |
| 2024 | 5.0 | Growth slowed as some biopharmaceutical companies reassessed their AI integration strategies. |
| 2025 | 6.4 | The market rebounded with renewed investments in AI-driven drug discovery projects. |
| 2026 | 5.1 | A slight slowdown occurred as companies adjusted to new AI regulations and standards. |
| 2027 | 9.0 | Demand surged as more biopharmaceutical companies adopted AI for genetic analysis. |
| 2028 | 7.5 | Growth decelerated as the 'AI in Biotech Initiative' began to stabilise market expansions. |
| 2029 | 10.1 | AI applications in drug discovery peaked, driving unprecedented market growth. |
| 2030 | 6.0 | The market experienced a slowdown as companies focused on optimising existing AI tools. |
| 2031 | 6.8 | Increased collaborations in the biotech sector spurred further growth in AI adoption. |
| 2032 | 9.3 | A resurgence in AI applications is expected as new funding initiatives from the 'AI in Biotech Initiative' are launched. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China AI for Biotech Market Synopsis
AI for Biotech in China encompasses the use of artificial intelligence technologies in biotechnology research and development. Key applications include drug discovery, genetic analysis, and improvements in laboratory efficiency. The China AI for Biotech Market is expanding due to substantial investments from biopharmaceutical companies and supportive government initiatives. With a market value of approximately 1.5 trillion CNY in 2022, the demand is fuelled by the integration of AI technologies into research institutions. The Beijing-Tianjin-Hebei region acts as a hub for biotech innovation, encouraging collaboration and development.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increased funding for AI-driven drug discovery projects is driving demand for advanced technologies. | Driver | High | Drug Discovery |
| The integration of AI algorithms in genetic analysis enhances research capabilities. | Driver | High | Genetic Engineering Labs |
| The rise of AI algorithms presents opportunities for biotech firms to improve data processing. | Opportunity | Medium | AI Algorithms |
| Growing partnerships in Guangdong province are creating new avenues for AI applications. | Opportunity | High | Biotech Cloud Platforms |
| Integration challenges with existing workflows can slow down AI adoption in biotech. | Restraint | Medium | Genomics Firms |
| Compliance with information security standards increases operational costs for biotech firms. | Restraint | High | Biopharmaceutical Companies |
| Limited access to advanced AI technologies restricts innovation in smaller biotech firms. | Challenge | High | Academic Biotech Research Centers |
| High competition may lead to pricing pressures, affecting profitability for biotech companies. | Challenge | Medium | Biopharmaceutical Companies |
Evaluation of Drivers in China AI for Biotech Market (2026–2032)
The factors lifting demand, and the evidence behind each, are summarised below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Government funding for AI research in biotechnology drives development. | AI Algorithms | The National Natural Science Foundation of China allocates 10 billion CNY annually to support AI research. |
| The biopharmaceutical market's growth fuels demand for AI-driven drug discovery. | Drug Discovery | The market was valued at approximately 1.5 trillion CNY in 2022, driving investments in AI. |
| Increased adoption of AI tools in genetic engineering labs improves research outcomes. | Genetic Engineering Labs | Approximately 70% of genetic engineering labs are integrating AI tools into their workflows. |
| The AI in Biotech Initiative promotes collaboration between research institutions and biotech firms. | Biotech Cloud Platforms | Launched in 2021, this initiative encourages the use of AI in life sciences. |
| Growing interest in AI applications for clinical trials enhances patient recruitment efficiency. | Genomics Firms | AI algorithms are increasingly used to streamline data analysis in clinical settings. |
The National Natural Science Foundation allocates 10 billion CNY annually to support AI research, boosting innovation in the sector. As the biopharmaceutical market was valued at 1.5 trillion CNY in 2022, firms are investing heavily in AI-driven drug discovery. Approximately 70% of genetic engineering labs are integrating AI tools, improving research capabilities.
Evaluation of Restraints in China AI for Biotech Market
The following restraints limit how fast demand can grow.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Integration challenges with existing workflows can slow down AI adoption in biotech. | Genomics Firms | Many firms struggle to adapt their processes to incorporate new AI technologies effectively. |
| Compliance with information security standards increases operational costs for biotech firms. | Biopharmaceutical Companies | ISO/IEC 27001 compliance requires investment in training and systems, affecting budgets. |
| Limited access to advanced AI technologies restricts innovation in smaller biotech firms. | Academic Biotech Research Centers | Smaller entities often lack the resources to acquire advanced AI tools. |
| High competition may lead to pricing pressures, affecting profitability for biotech companies. | Biopharmaceutical Companies | Intense competition among firms can result in reduced margins and increased costs. |
| Regulatory hurdles can delay the implementation of AI solutions in biotech applications. | Genetic Engineering Labs | Navigating complex regulations can slow down the integration of new technologies. |
China AI for Biotech Market Challenges
In the China AI for Biotech market, regulatory hurdles create substantial compliance costs, which can reach around 15% of project budgets for biopharmaceutical companies. Buyers face challenges in sourcing AI solutions that meet these regulations, causing delays in technology adoption and hindering research timelines. Many biopharmaceutical companies struggle with integrating AI technologies, leading to a 20% drop in operational efficiency as they fail to implement necessary tools effectively. Skills shortages are prevalent, with over 60% of firms reporting difficulties in recruiting qualified personnel, which stifles innovation and extends research and development cycles.
Trends in the China AI for Biotech Market
Buyers and suppliers in the China AI for Biotech Market are adjusting to the following trends.
- Shift from Traditional Methods to AI-Driven Processes: The adoption of AI technologies is reshaping drug discovery processes in China, with over 300 registered biopharmaceutical companies actively utilising AI. This transition is set to improve efficiency and accuracy in research.
- Increased Collaboration in AI Biotech: The Guangdong province has witnessed over 50 partnerships formed in 2023, driving AI biotech collaborations. This trend is promoting innovation and broadening the application of AI across various biotech fields.
- Growing Demand for AI-Enhanced Genetic Analysis: In 2023, approximately 70% of genetic engineering labs in China are integrating AI tools. This trend indicates a shift towards data-driven approaches in genetic research.
- Expansion of Biotech Cloud Platforms: Biotech Cloud Platforms are gaining popularity, with a market share of 43% projected for 2025. This trend facilitates easier access to AI tools for research institutions and companies.
Investment Opportunities in the China AI for Biotech Market
Several openings in the China AI for Biotech Market merit attention from investors.
- AI Algorithms for Improved Data Processing: AI algorithms present an opportunity for biotech firms to improve data processing capabilities. With the rise of AI applications, biopharmaceutical companies can use these tools for better outcomes.
- Biotech Cloud Platforms for Research Institutions: Biotech Cloud Platforms are essential for research institutions seeking advanced AI tools. The Beijing-Tianjin-Hebei region is a key area for investment, facilitating access to innovative solutions.
- Investment in AI-Driven Drug Discovery: The AI-driven drug discovery market is expanding, with 5 billion CNY allocated in 2023 for related projects. Biopharmaceutical companies can invest in this area to improve their research capabilities.
- Collaborative Opportunities in Guangdong Province: The Guangdong province is witnessing a rise in AI biotech collaborations, with over 50 partnerships formed in 2023. Companies can enter this market through local partnerships to share resources.
Government Initiatives in the China AI for Biotech Market
The Ministry of Science and Technology's 'AI in Biotech Initiative' launched in 2021 promotes the integration of AI technologies in biotechnology. This initiative aims to improve research capabilities and encourage collaboration among biopharmaceutical companies. Additionally, the 'Digital Health Strategy' introduced by the National Health Commission in 2022 focuses on integrating AI technologies in healthcare and biotech sectors, ensuring that firms comply with emerging standards. These measures collectively support the growth of AI applications in the industry, facilitating advancements in drug discovery and genetic analysis.
Various funding programs aimed at enhancing AI applications benefit buyers in the biopharmaceutical sector. The Ministry of Science and Technology announced a 3 billion CNY funding program in 2023 to support AI-driven biotech innovations. This funding is vital for research institutions and companies looking to integrate advanced technologies into their operations. The China National Center for Bioinformation also plays a role in approving projects that utilise AI for genomic research, ensuring that buyers have access to the latest tools and methodologies.
Future Insight of the China AI for Biotech Market
By 2032, buyers and suppliers in the China AI for Biotech market can anticipate transformative changes driven by increased government funding and strategic initiatives. The National Natural Science Foundation's annual budget of 10 billion CNY for AI research will enhance collaboration among research institutions. The 'AI in Biotech Initiative' launched by the Ministry of Science and Technology will encourage broader AI applications in life sciences. The emergence of over 50 AI biotech collaborations in Guangdong province will boost innovation and accelerate advancements in drug discovery.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Application Area – Drug Discovery Dominated, CRISPR Analysis Expected to Grow Fastest
According to Ravi Bhandari, Research Head at 6Wresearch, with a 49% revenue share in 2025, Drug Discovery was the largest application area category. Drug discovery holds the largest share due to its critical role in identifying new therapeutic candidates, with substantial investment from the biopharmaceutical sector. The Chinese government allocated 5 billion CNY in 2023 to support AI-driven drug discovery projects, highlighting its importance. The quickest growth will come from CRISPR Analysis, forecast to expand at a CAGR of 10.2% between 2026 and 2032. CRISPR analysis is experiencing rapid growth as AI optimises gene editing processes, which are increasingly vital for advanced genetic research. The integration of AI tools in approximately 70% of genetic engineering labs in China is a clear indicator of this trend. Suppliers should focus on developing AI solutions tailored for drug discovery to capture the substantial market share.
By Technology Type – Machine Learning Dominated, AI Algorithms Expected to Grow Fastest
The largest technology type category in 2025 was Machine Learning, with a 45% share of total revenue. Machine learning holds the largest share because it is the core technology that enables predictive analytics in biotechnology, which is essential for advancing research capabilities. Its widespread adoption among over 300 registered biopharmaceutical companies illustrates its critical importance in the market. AI Algorithms are set to record the highest CAGR in this split, 8.9% over 2026–2032. AI algorithms are witnessing rapid growth as they are essential for processing large datasets, which is crucial for effective applications in biotechnology. The increasing use of AI algorithms in clinical trials to enhance data analysis highlights this upward trend. Suppliers should prioritise the development of machine learning solutions to meet the rising demands of the biotechnology sector.
By Distribution Channel – Biotech Cloud Platforms Dominated, Specialized B2B Portals Expected to Grow Fastest
Biotech Cloud Platforms held a 43% share of the China AI for Biotech Market by distribution channel in 2025. Biotech cloud platforms dominate the market share as they provide vital access to AI tools, significantly improving collaboration and efficiency for researchers. The concentration of numerous AI biotech startups in the Shanghai Zhangjiang Hi-Tech Park reinforces the strength of this distribution channel. Over 2026–2032, Specialized B2B Portals are expected to post the fastest growth, at a CAGR of 10.0%. Specialised B2B portals are experiencing rapid growth as they facilitate networking and collaboration among biotech professionals, which is essential for driving innovation. The establishment of over 50 partnerships in the Guangdong province in 2023 exemplifies this swift expansion. Suppliers must enhance their offerings on biotech cloud platforms to effectively address the increasing demand from users.
By End User – Biopharmaceutical Companies Dominated, Genetic Engineering Labs Expected to Grow Fastest
Biopharmaceutical Companies accounted for a 48% market share by end user in 2025. Biopharmaceutical companies represent the largest share as they are the primary users of AI technologies for drug development, playing a pivotal role in shaping the market. The substantial valuation of China's biopharmaceutical market at approximately 1.5 trillion CNY underscores their dominant position. Genetic Engineering Labs are projected to grow fastest, at a CAGR of 10.4% during 2026–2032. Genetic engineering labs are rapidly growing as they increasingly adopt AI to improve their research capabilities, reflecting the sector's rising significance. The integration of AI tools in these labs indicates their expanding influence within the market. Buyers should pursue strategic partnerships with biopharmaceutical companies to fully capitalise on the benefits of AI technologies.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China AI for Biotech Market Outlook
- Market Size of China AI for Biotech Market, 2025
- Forecast of China AI for Biotech Market, 2032
- Historical Data and Forecast of China AI for Biotech Revenues & Volume for the Period 2022 - 2032F
- China AI for Biotech Market Trend Evolution
- China AI for Biotech Market Drivers and Challenges
- China AI for Biotech Price Trends
- China AI for Biotech Porter's Five Forces
- China AI for Biotech Industry Life Cycle
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Application Area for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Drug Discovery for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By CRISPR Analysis for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By DNA Sequencing for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Protein Structure Prediction for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Technology Type for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Machine Learning for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By AI Algorithms for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Deep Neural Networks for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Reinforcement Learning for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Distribution Channel for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Biotech Cloud Platforms for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Specialized B2B Portals for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By SaaS Licensing for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Direct Institutional Sales for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Biopharmaceutical Companies for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Genetic Engineering Labs for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Genomics Firms for the Period 2022 - 2032F
- Historical Data and Forecast of China AI for Biotech Market Revenues & Volume By Academic Biotech Research Centers for the Period 2022 - 2032F
- China AI for Biotech Import Export Trade Statistics
- Market Opportunity Assessment By Application Area
- Market Opportunity Assessment By Technology Type
- Market Opportunity Assessment By Distribution Channel
- Market Opportunity Assessment By End User
- China AI for Biotech Top Companies Market Share
- China AI for Biotech Competitive Benchmarking By Technical and Operational Parameters
- China AI for Biotech Company Profiles
- China AI for Biotech Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Application Area
- Drug Discovery
- CRISPR Analysis
- DNA Sequencing
- Protein Structure Prediction
By Technology Type
- Machine Learning
- AI Algorithms
- Deep Neural Networks
- Reinforcement Learning
By Distribution Channel
- Biotech Cloud Platforms
- Specialized B2B Portals
- SaaS Licensing
- Direct Institutional Sales
By End User
- Biopharmaceutical Companies
- Genetic Engineering Labs
- Genomics Firms
- Academic Biotech Research Centers
